AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Allogene Therapeutics, Inc. Director's Dealing 2021

May 20, 2021

33378_dirs_2021-05-20_5abb508e-f5cf-41d9-b41a-374503a83f69.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Allogene Therapeutics, Inc. (ALLO)
CIK: 0001737287
Period of Report: 2021-05-18

Reporting Person: Bhavnagri Veer (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-18	Common Stock	M	5000	$2.27	Acquired	426353	Direct
2021-05-18	Common Stock	S	5000	$30.00	Disposed	421353	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-18	Stock Option (Right to Buy)	$2.27	M	5000	Disposed	2028-06-25	Common Stock (5000)	Direct

Footnotes

F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2020.

F2: 25% of the shares subject to the stock option vested on April 6, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.